| Document |
Document Title |
|
WO/2005/025556A2 |
A method of treating a subject for a bacterial infection includes administering to a subject in need of treatment for a bacterial infection an effective amount of a compound represented by structural formula (I), or a pharmaceutically ac...
|
|
WO/2005/025507A2 |
This invention relates to dihydropyridine compounds of formula: (I) or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein A2, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, and m are defined herein...
|
|
WO/2005/025572A1 |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
|
WO/2005/026126A1 |
CRF antagonists containing as the active ingredient compounds represented by the general formula (I): (I) wherein A is an optionally substituted 5- or 6-membered monocycle; B is a 5- to 7-membered monocyclic unsaturated heterocycle which...
|
|
WO/2005/021536A2 |
The invention relates to new compounds of the general formula (I), which are strong DPP-IV enzyme inhibitors.
|
|
WO/2005/018561A2 |
The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, an...
|
|
WO/2005/016343A1 |
A series of substituted phenanthridine derivatives has been synthesized by converting the amines at the 3- and 8- positions of ethidium bromide into guanidine, pyrrole, urea, and various substituted ureas. The resulting derivatives exhib...
|
|
WO/2005/012252A1 |
Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6, R7 and R8 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2005/012253A1 |
Compounds of a certain formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6, R7 and R8 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2005/009951A2 |
The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory a...
|
|
WO/2005/009949A2 |
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of...
|
|
WO/2005/009398A2 |
The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal f...
|
|
WO/2005/007670A1 |
A method for preparing a 1-androstene derivative which comprises reacting a 2-iodo-androstane derivative with an oxidizing agent while maintaining the pH of the reaction mixture at a specific range gives the 1-androstene derivative with ...
|
|
WO/2005/007630A2 |
This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions conta...
|
|
WO2004096802A9 |
Disclosed are tetrahydro-beta-carboline derivatives such as structural formula I, pharmaceutical compositions comprising them and methods of treating bacterial infections. The disclosed compounds are inhibitors of PPAT (phosphopantethein...
|
|
WO/2005/005606A2 |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
|
WO/2005/005380A2 |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
WO/2005/003086A2 |
The invention relates to the production of quinoline compounds containing sulfonic acid groups, said quinoline compounds, and the conversion thereof into dyes containing sulfonic acid groups. The inventive dyes are used especially for ma...
|
|
WO/2004/113391A2 |
The present invention is directed to methods of preparation of sulfonate derivatized compounds, e.g., 3-amino-l-propanesulfonic acid and 1,3-propanedisulfonic acid disodium salt with increased purity, with reduced potential for toxic by-...
|
|
WO/2004/110449A1 |
The invention provides certain aporphine and oxoaporphine for preparing medicine which can be used for ischemic disease prevention and treatment. The pharmacological mechanism of said compounds is to keep or increase endothelial nitric o...
|
|
WO/2004/108681A1 |
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
|
|
WO/2004/101570A1 |
The present invention relates to sulfur-containing naphthoylimide derivatives, the preparation and the use thereof. By expanding the conjugate plane of the naphthoylimide with condensed 5- or 6-member aromatic heterocyclic ring and / or ...
|
|
WO/2004/100891A2 |
The synthesis and biological activity of benzoisoindoloisoquinolone compounds are described. The synthesis and biological activity of C-11-substituted indenoisoquinolones are also described. Indenoisoquinolones substituted at C-11 are pr...
|
|
WO/2004/091485A2 |
This invention relates to treating inflammatory and immune diseases with certain aminoquinoline compounds that bind to CXCR3 receptors. The aminoquinoline compounds are covered by the formula (I) shown below. Each variable is defined in ...
|
|
WO/2004/089307A2 |
Certain novel N-acylated spiropiperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment,...
|
|
WO/2004/089908A2 |
The subject invention relates to 3-azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid re...
|
|
WO/2004/089909A1 |
The subject invention relates to 2-azabicyclo[3.3.1 ]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid r...
|
|
WO/2004/089926A2 |
Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemi...
|
|
WO/2004/086861A2 |
It has been found that sampangine and related analogs such as benzo [4,5] sampangine, 4-bromosampangine and 4-methoxysampangine may be used as effective fungicidal agents for plants. Fungicidal plant compositions and methods of using the...
|
|
WO2003068748A9 |
The present invention relates to compounds of formula (I), wherein R, R<2>, R<3> and R<4 >are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prop...
|
|
WO/2004/082698A1 |
The invention relates to alkaloid reaction products obtainable in a process wherein alkaloids are reacted with an alkylating agent, preferably thiotepa, whereafter unreacted alkylating agent and other water-soluble compounds are removed ...
|
|
WO/2004/082682A1 |
The present invention is directed to compounds of the formulas I and II : wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R25, R26, Y, Z, l, m, n and the broken lines are as defined herein which are useful as mo...
|
|
WO/2004/078712A2 |
The invention relates to Isoquinoline Derivatives; compositions comprising an effective amount of an Isoquinoline Derivative; and methods for treating or preventing an inflammatory disease or a reperfusion disease comprising the administ...
|
|
WO/2004/076411A2 |
The present invention is directed to compounds of formulae (I and II) (wherein A, D, E. X, l, m, n and R1 through R18 are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are u...
|
|
WO/2004/072046A2 |
The present invention relates to specific compounds and pharmaceutically acceptable salts thereof; methods for synthesizing these compounds; compositions comprising at least one of these compounds or a pharmaceutically acceptable salt th...
|
|
WO2004017922B1 |
Novel tricyclic cannabinoid compounds are presented. Some of these compounds exhibit fluorescence properties. The fluorescent cannabinoid compounds are typically endogenously fluorescent. Some of these compounds, when administered in a t...
|
|
WO/2004/063164A1 |
A process for the preparation of aryl fused polycyclic lactams of formulaI which are useful intermediates in the synthesis of aryl fused azapolycyclic compounds as agents for the treatment of neurological and psychological disorders.
|
|
WO/2004/058757A1 |
Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1 or 2, and R1, R3, R4, R12 and R14 are d...
|
|
WO/2004/058756A1 |
Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16,...
|
|
WO/2004/058719A1 |
A process for the preparation of benzocydoheptapyridin-11-ones of the general formula (III) wherein R1, R2, R3, R4, R5, R6 and R7 are independently selected from one or more of the following groups: hydrogen, halogen, C1-C6 alkyl, C1-C6 ...
|
|
WO/2004/056362A2 |
Compounds of the formula (1), in which R1 is hydrogen, methyl or hydroxymethyl, R2a and R2b are both hydrogen or together denote a bond, R3 is 1-7C-alkyl, R4 is 1-7-alkyl and R5 is 1-7C-alkyl, and its salts, are valuable intermediates fo...
|
|
WO/2004/056797A1 |
The present invention relates to compounds of the general formula (II) and salts and physiologically functional derivatives thereof, for the use as a medicament.
|
|
WO/2004/056746A1 |
The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein A is a non-aromatic ring system containing 4 to 8 carbon atoms, wherein the ring system comprises...
|
|
WO/2004/056747A1 |
The present invention relates to compounds of the general formula (I), or salts or isomeres thereof, wherein A is a 4-8 membered non-aromatic ring system, to compounds of the general formula (II), or salts or isomeres thereof, wherein A ...
|
|
WO/2004/055015A1 |
Aminocyanopyridine compounds are described which can inhibit mitogen activated protein kinase-activated protein kinase-2. Pharmaceutical compositions and kits that contain these compounds are also described.
|
|
WO/2004/054981A1 |
The present invention provides NPY-5 receptor antagonists having a Formula (I) Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor antagonists are also p...
|
|
WO/2004/054978A1 |
It is intended to provide a compound to be used as an imaging diagnosis probe for a disease with tau protein accumulation, its salt or a solvate thereof, and a composition and a kit containing the same. It is also intended to provide a s...
|
|
WO/2004/052850A2 |
Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/052862A1 |
Because of having an effect of controlling CXCR4, compounds represented by the following general formulae (I) and (II), salts thereof, N-oxides thereof, solvates thereof or prodrugs of the same and medicinal compositions containing the s...
|
